Article Text

Download PDFPDF
Glycosylation defects as an emerging novel cause leading to a limb-girdle type of congenital myasthenic syndromes
  1. Kinji Ohno
  1. Correspondence to Professor Kinji Ohno, Department of Neurogenetics, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan; ohnok{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Late-onset limb-girdle muscle weakness with tubular aggregates, effective cholinesterase inhibitors and spared extraocular muscles are hallmarks of glycosylation defect-associated congenital myasthenia.

Congenital myasthenic syndromes (CMS) are heterogeneous disorders caused by germline mutations in genes encoding molecules expressed at the neuromuscular junction. In all, 14 genes (CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, RAPSN, SCN4A, MUSK, DOK7, PLEC1, LAMB2, COLQ, CHAT, AGRN) had been identified in association with CMS by 2006. All the identified molecules function exclusively at the neuromuscular junction except for choline acetyltransferase, which is also essential for cholinergic synapses in the central nervous system. …

View Full Text


  • Author note Cossins and colleagues6 have recently reported mutations in the other glycosylation enzymes, ALG2 and ALG14, in seven patients with a limb-girdle pattern of muscle weakness with eye, facial, and bulbar muscles largely spared and with favorable responses to cholinesterase inhibitors.

  • Competing interests None.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles

  • Neuromuscular
    Sarah Finlayson Jacqueline Palace Katsiaryna Belaya Timothy J Walls Fiona Norwood Georgina Burke Janice L Holton Samuel I Pascual-Pascual Judith Cossins David Beeson